Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients

PURPOSE: The aim of this study was to evaluate the risk of immune-related adverse events (irAEs) among cancer patients receiving nivolumab-plus-ipilimumab therapy and nivolumab monotherapy. PATIENTS AND METHODS: PubMed and Web of Science were searched for related studies from inception to June 2018....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shi, Khanal, Samrat, Zhang, Haijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362938/
https://www.ncbi.nlm.nih.gov/pubmed/30774357
http://dx.doi.org/10.2147/TCRM.S193338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362938/
https://www.ncbi.nlm.nih.gov/pubmed/30774357
http://dx.doi.org/10.2147/TCRM.S193338

Ejemplares similares